Phase 2a results for Namodenoson show durable survival and a clean safety profile in patients who had exhausted standard treatments Can-Fite Biopharma Ltd ADR (NYSE…
AbbVie Strikes an All-Cash Deal AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash transaction worth roughly $10.9 billion. Under the…
Abivax (Nasdaq: ABVX) jumped more than 24% on Wednesday, clawing back a chunk of the brutal selloff that erased over a third of its value…
Jade Biosciences (NASDAQ: JBIO) kicked off the week with a bang, reporting positive interim results Monday from its Phase 1 trial of JADE101, an experimental…
Outlook Therapeutics, Inc. (NASDAQ: OTLK) saw its shares jump 50% on Monday after the company secured a major regulatory win — the U.S. Food and…
Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced encouraging early pilot results for ViraxImmune™, its blood-based test under development for Long…
Immunovant, Inc. (NASDAQ: IMVT) shares jumped 20% on Wednesday after the company released encouraging preliminary results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis. Strong…
InMed Pharmaceuticals (NASDAQ: INM) and Mentari Therapeutics announced today that they have signed a definitive all-stock merger agreement, uniting Mentari’s differentiated migraine pipeline with InMed’s…
Design Therapeutics, Inc. (NASDAQ:DSGN) jumped 27% higher Monday after the company unveiled positive four-week data from its RESTORE-FA trial of DT-216P2 in patients with Friedreich…
The Caris Lookback Program flagged 13,293 patients as potentially eligible for newly approved targeted therapies across 10 tumor types Caris Life Sciences® (NASDAQ: CAI), a…
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced on Monday that its pivotal Phase 3 Bria-ABC study has screened more than 315 patients and…
Zai Lab Limited (NASDAQ: ZLAB) shares climbed 7.2% on Monday after the company announced that the U.S. Food and Drug Administration granted Fast Track Designation…